{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:44:29Z","timestamp":1780386269008,"version":"3.54.1"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>We conducted weekly surveillance for pre\u2010specified adverse events following receipt of the 2012\u20132013 influenza vaccines in the Vaccine Safety Datalink (VSD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For each outcome, risk intervals (i.e., period after vaccination with a potentially increased risk) were defined on the basis of biologic plausibility and prior literature. Seizures following inactivated influenza vaccine (IIV) were monitored in children in three age groups (6\u201323\u2009months, 24\u201359\u2009months, and 5\u201317\u2009years) using a self\u2010controlled risk interval design. We also monitored for Guillain\u2013Barr\u00e9 syndrome, encephalitis, and anaphylaxis following IIV in patients \u22656\u2009months of age using a cohort design with historical controls. In the risk intervals following live attenuated influenza vaccine (LAIV), we collected weekly counts of Guillain\u2013Barr\u00e9 syndrome, encephalitis, and anaphylaxis in patients ages 2\u201349. Among LAIV vaccinees, numbers of expected events based on rates in historical controls were calculated, adjusted for age and site.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the end of surveillance, approximately 3.6 million first doses of IIV and 250\u2009000 first doses of LAIV had been administered in the VSD. No elevated risks were identified in risk intervals following 2012\u20132013 IIV, as compared with a self\u2010matched control interval or to historical controls. For each outcome, fewer than three events occurred in the risk interval following 2012\u20132013 LAIV, and we thus were unable to estimate measures of relative risks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No increased risk was identified for any of the pre\u2010specified outcomes following 2012\u20132013 influenza vaccinations in the VSD. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3575","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T21:56:02Z","timestamp":1391550962000},"page":"548-553","source":"Crossref","is-referenced-by-count":46,"title":["Absence of associations between influenza vaccines and increased risks of seizures, Guillain\u2013Barr\u00e9 syndrome, encephalitis, or anaphylaxis in the 2012\u20132013 season"],"prefix":"10.1002","volume":"23","author":[{"given":"Alison Tse","family":"Kawai","sequence":"first","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kulldorff","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vellozzi","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Immunization Safety Office  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Immunization Safety Office  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Baxter","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Northern California  Oakland CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Belongia","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Foundation  Marshfield WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Daley","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Colorado  Denver CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Southern California  Pasadena CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Naleway","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Northwest  Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Nordin","sequence":"additional","affiliation":[{"name":"Health Partners Research Foundation  Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston MA USA"},{"name":"Boston Children's Hospital  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.027"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.040"},{"issue":"33","key":"e_1_2_9_4_1","first-page":"1128","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee On Immunization Practices (ACIP), 2011","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"e_1_2_9_5_1","first-page":"613","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee On Immunization Practices (ACIP)\u2010\u2010United States, 2012\u201013 influenza season","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1722H"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181af8605"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-0665"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp345"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2011.04.004"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/07474946.2011.539924"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2133"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3780"},{"issue":"9","key":"e_1_2_9_14_1","first-page":"258","article-title":"Licensure of a 13\u2010valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children \u2010 Advisory Committee On Immunization Practices (ACIP), 2010","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.06.092"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62189-8"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3575","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T08:49:53Z","timestamp":1696495793000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1002\/pds.3575"],"URL":"https:\/\/doi.org\/10.1002\/pds.3575","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]}}}